Evaluating PSMA in Metastatic Triple Negative Breast Cancer
Evaluation of PSMA Expression in Triple Negative Breast Cancer Patients Using 18 F-DCFPyL-PET/CT
This study is testing if a special imaging technique can help find cancer spots in patients with metastatic triple negative breast cancer to see if new treatments targeting those spots could work.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | Female |
| Sponsor | University of Iowa Academic / other |
| Locations | 1 site (Iowa City, Iowa) |
| Trial ID | NCT06586047 on ClinicalTrials.gov |
What this trial studies
This research aims to assess the expression of Prostate Specific Membrane Antigen (PSMA) in patients with metastatic Triple Negative Breast Cancer (TNBC) using advanced PET imaging techniques. The study will enroll thirty patients who will undergo two PET scans: an FDG PET/CT and an 18F-DCFPyL-PET/CT, to compare the detection rates of PSMA-avid lesions against FDG-avid lesions. The goal is to determine if PSMA-based therapies could be a viable treatment option for TNBC, potentially leading to new clinical trials. Each patient will participate for a maximum of four weeks, with two visits required for imaging.
Who should consider this trial
Good fit: Ideal candidates are females aged 18 and older with distantly metastatic TNBC who have FDG positive metastatic lesions.
Not a fit: Patients with known active other malignancies or those unable to tolerate PET/CT procedures may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new treatment options for patients with metastatic TNBC by utilizing PSMA-targeted therapies.
How similar studies have performed: While there is emerging evidence of PSMA expression in breast cancer, this approach is relatively novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female \>= 18 years of age * Patients in distantly metastatic TNBC based on the initial diagnosis biopsy. * Patient should have FDG positive metastatic lesions on the initial PET/CT scan performed in this study to be further included. Exclusion Criteria: * Patients with known active other malignancy. * Unable to tolerate PET/CT procedure. * Pregnant or breastfeeding. * Patients with any medical condition that might compromise the safety of subject during PET acquisitions.
Where this trial is running
Iowa City, Iowa
- University of Iowa Healthcare — Iowa City, Iowa, United States (Recruiting)
Study contacts
- Study coordinator: Ahmad Shariftabrizi, M.D.
- Email: ashariftabrizi@uiowa.edu
- Phone: 319-887-4942
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.